Platelet Microparticles: A Potential Predictive Factor of Survival in Hormone-Refractory Prostate Cancer Patients Treated with Docetaxel-Based Chemotherapy

European Urology

Volumn 56, Issue 3, 2009, Pages 479-485

  Helley, Dominique ^a,b,c   Banu, Eugeniu ^a   Bouziane, Abdelkader ^a   Banu, Adela ^a   Scotte, Florian ^a   Fischer, Anne Marie ^a,b,c   Oudard, Stéphane ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Hormone refractory prostate cancer; Platelet microparticles; Predictive factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CAPECITABINE; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; MONOCLONAL ANTIBODY; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; FLOW CYTOMETRY; FRANCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; THROMBOCYTE ACTIVATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT FAILURE;

EID: 67651015630     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.038     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
3. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355 (2000) 1491-1498
4. Pienta K., and Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55 (2005) 300-318 quiz 323-5
5. Di Lorenzo G., Autorino R., Perdonà S., et al. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. Eur Urol 52 (2007) 1020-1027
6. Fosså S.D., Jacobsen A.-B., Ginman C., et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 52 (2007) 1691-1699
7. Kikuno N., Urakami S., Nakamura S., et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 51 (2007) 1252-1258
8. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., and Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A 98 (2001) 3352-3357
9. Nash G.F., Turner L.F., Scully M.F., and Kakkar A.K. Platelets and cancer. Lancet Oncol 3 (2002) 425-430
10. Huo Y., Schober A., Forlow S.B., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9 (2003) 61-67
11. Nierodzik M., and Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10 (2006) 355-362
12. Tesselaar M., Romijn F., Van Der Linden I., Prins F., Bertina R., and Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 5 (2007) 520-527
13. Verheul H.M., Jorna A.S., Hoekman K., Broxterman H.J., Gebbink M.F., and Pinedo H.M. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96 (2000) 4216-4221
14. Kim H.K., Song K.S., Chung J.H., Lee K.R., and Lee S.N. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 124 (2004) 376-384
15. Brill A., Dashevsky O., Rivo J., Gozal Y., and Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 67 (2005) 30-38
16. Dahut W., Gulley J., Arlen P., et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22 (2004) 2532-2539
17. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143 (1993) 401-409
18. Shariat S., Anwuri V., Lamb D., Shah N., Wheeler T., and Slawin K. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22 (2004) 1655-1663
19. George D.J., Halabi S., Shepard T.F., et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7 (2001) 1932-1936
20. Calabrò F., and Sternberg C.N. Current indications for chemotherapy in prostate cancer patients. Eur Urol 51 (2007) 17-26
21. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
22. Sciarra A., and Salciccia S. New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?. Eur Urol 52 (2007) 945-947
23. VanWijk M.J., VanBavel E., Sturk A., and Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 59 (2003) 277-287
24. Villmow T., Kemkes-Matthes B., and Matzdorff A.C. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res 108 (2002) 139-145
25. Kim H.K., Song K.S., Park Y.S., et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 39 (2003) 184-191
26. Suzuki K., Aiura K., Kitagou M., et al. Platelets counts closely correlate with the disease-free survival interval of pancreatic cancer patients. Hepatogastroenterology 51 (2004) 847-853
27. Bamias A., Bozas G., Antoniou N., et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 53 (2008) 323-332
28. Oudard S., Banu E., Beuzeboc P., et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23 (2005) 3343-3351
29. Baj-Krzyworzeka M., Majka M., Pratico D., et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 30 (2002) 450-459
30. Sierko E., and Wojtukiewicz M. Inhibition of platelet function: does it offer a chance of better cancer progression control?. Semin Thromb Hemost 33 (2007) 712-721
31. Langer F., Kyoung-Hwan Chun F., Amirkhosravi A., et al. Plasma tissue factor antigen in localized prostate cancer: Distribution, clinical significance and correlation with haemostatic activation markers. Thromb Haemost 97 (2007) 464-470
32. Sinauridze E., Kireev D., Popenko N., et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 97 (2007) 425-434